Glaxo's Witty Lists 'Fundamentals' For Consumer Business Prowess
This article was originally published in The Tan Sheet
Executive Summary
Andrew Witty tells analysts Glaxo is strong in areas critical to success in the consumer health products space: margin, scale and potential OTC switches. The Flonase Allergy Relief OTC switch shows "nobody is switching products better than GSK," he says.
You may also be interested in...
CEO Witty's 2017 Exit Could Hasten Glaxo's Consumer Business Decision
Glaxo CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change. His biggest legacy could be the multi-asset swap he orchestrated with Novartis in 2014 that created a consumer health care JV with the Swiss firm.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.